C. David Nicholson, B.S., Ph.D.
Senior Vice President and Head, Worldwide Licensing and Knowledge Management
Dr. David Nicholson’s career spans more than 30 years in
pharmaceutical research and development. Dr. Nicholson joined Merck in 2009 as S.V.P., Global Licensing and Knowledge Management. Prior, Dr. Nicholson served as S.V.P., Global Project Management and Drug Safety for Schering-Plough following its 2007 acquisition of Organon where he lead research and development for the company. Dr. Nicholson’s 14-year tenure at Organon took him from Newhouse, Scotland, to Oss, Netherlands, where he also held positions that included pharmacology department head, head of research in the Netherlands and head of global research.
Steven J. Projan, Ph.D., FAAM
Innovative Medicines Head of Infectious Diseases and Vaccines
Dr. Steve Projan joined MedImmune in 2010 as S.V.P., R&D and Innovative Medicines Head of Infectious Diseases and Vaccines following two years at Novartis as Global Head of Infectious Diseases and 15 years at Wyeth. Prior to Dr. Projan’s work in industry he had a 14-year academic career at the Public Health Research Institute and has over 110 publications to his credit. At Wyeth, Dr. Projan was the Biology Team Leader of the Glycylcycline Discovery Team that produced tigecycline, an antibacterial drug for the treatment of drug resistant bacterial infections.
Morten Sogaard, Ph.D.
Executive Director & Head Biotechnology Unit, External R&D Innovation (ERDI)
Pfizer Worldwide Research and Development
In close collaboration with Pfizer’s CSOs, External R&D Innovation identifies, evaluates and funds Pfizer’s large R&D collaborations. Morten’s team is responsible for technology and oncology collaborations.
Morten received his Ph.D. in biochemistry from the University of Copenhagen. Following post-doctoral studies at Sloan-Kettering Institute in New York, he moved to Pharmacia in Sweden, where he was section head and project leader for oncology antibody therapeutics. In 1998, he moved to AstraZeneca, Sweden as head of the Molecular Sciences Department , responsible for genomics, genetics and protein family research, and head of AZ’s global nuclear receptor program. In 2004 Morten moved to Boehringer Ingelheim in Ridgefield, CT as VP and global head of enabling technology and a member of BI’s global research leadership team. In this role he helped build a world-wide enabling technology function comprising global technology skill centers, research informatics and an infrastructure for biologics research. Morten has been with Pfizer since 2009.